nach oben

Breast Cancer Research and Treatment

Erschienen in:

13.01.2018 | Review

Breast cancer survivorship: state of the science

verfasst von: Kathy Pan, Arti Hurria, Rowan T. Chlebowski

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Only recently has breast cancer survivorship earned formal recognition as a research discipline. Complicating survivorship research is the frequent overlap between aging and treatment sequelae. The ACS/ASCO 2016 Breast Cancer Survivorship Care Guideline (Guideline) reflects comprehensive literature review through April 2015, while the jointly sponsored, inaugural Cancer Survivorship Symposium in 2016 (Symposium) reflects ongoing research activity in the area. Together, these platforms provide an opportunity to examine the use of randomized trials and controlled studies in survivorship care research.

Methods

All 236 citations from the Guideline and all 250 abstracts from the Symposium were reviewed independently by two authors and assigned to prospectively determined categories.

Results

Guideline citations were most frequently reviews (n = 88, 37.3%) and non-randomized, non-controlled studies (n = 51, 21.6%). Thirty-seven (15.7%) randomized trials were cited. Only 9% of Guideline recommendations were based on randomized clinical trial evidence, while 64% were based on evidence level "0" (expert opinion, clinical practice, etc.). Symposium abstracts consisted largely of non-randomized, non-controlled studies (n = 113, 45.2%), with ten completed randomized trials (4%). Few Guideline citations or Symposium abstracts incorporated matched, cancer-free controls.

Conclusions

Based on the literature underlying the ASCO Guideline as well as a survey of the Cancer Survivorship Symposium abstracts, a significant proportion of the survivorship literature at least through 2015 consisted of non-randomized, non-controlled studies. To optimally address survivorship issues, cancer therapy sequelae need to be distinguished from normal aging in studies incorporating cancer-free controls, and randomized clinical trials are needed to inform intervention strategies.

Nur mit Berechtigung zugänglich

(2008). In: Adler NE, Page AEK (eds) Cancer care for the whole patient: meeting psychosocial health needs. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC). https://doi.org/10.17226/11993

Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94(1):39–49CrossRefPubMed

Hewitt M, Greenfield S, Stovall E (2006) From cancer patient to cancer survivor: lost in transition. Committee on cancer survivorship: improving care and quality of life, institute of medicine and national research council. The National Academies Press, Washington, DC

Jassim GA, Whitford DL, Hickey A, Carter B (2015) Psychological interventions for women with non-metastatic breast cancer. Cochrane Database Syst Rev 5:CD008729. https://doi.org/10.1002/14651858.cd008729.pub2

Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P (2009) Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 18(Suppl 2):S1–11. https://doi.org/10.1016/S0960-9776(09)70002-5 CrossRefPubMed

Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW, Coleman RE (2011) Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 22(4):857–862. https://doi.org/10.1093/annonc/mdq541 CrossRefPubMed

Ahles TA, Li Y, McDonald BC, Schwartz GN, Kaufman PA, Tsongalis GJ, Moore JH, Saykin AJ (2014) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. Psychooncology 23(12):1382–1390. https://doi.org/10.1002/pon.3545 CrossRefPubMedPubMedCentral

Mandelblatt JS, Clapp JD, Luta G, Faul LA, Tallarico MD, McClendon TD, Whitley JA, Cai L, Ahles TA, Stern RA, Jacobsen PB, Small BJ, Pitcher BN, Dura-Fernandis E, Muss HB, Hurria A, Cohen HJ, Isaacs C (2016) Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer. https://doi.org/10.1002/cncr.30208 PubMedPubMedCentral

Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29(17):2327–2333. https://doi.org/10.1200/JCO.2010.33.0258 CrossRefPubMedPubMedCentral

10.

Hayes DF (2007) Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med 356(24):2505–2513. https://doi.org/10.1056/NEJMcp067260 CrossRefPubMed

11.

Nilsson G, Holmberg L, Garmo H, Terent A, Blomqvist C (2009) Radiation to supraclavicular and internal mammary lymph nodes in breast cancer increases the risk of stroke. Br J Cancer 100(5):811–816. https://doi.org/10.1038/sj.bjc.6604902 CrossRefPubMedPubMedCentral

12.

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH, Pharmacovigilance Study T (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293–1305. https://doi.org/10.1093/jnci/djs317 CrossRefPubMedPubMedCentral

13.

Lenihan DJ, Cardinale DM (2012) Late cardiac effects of cancer treatment. J Clin Oncol 30(30):3657–3664. https://doi.org/10.1200/JCO.2012.45.2938 CrossRefPubMed

14.

Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH (1999) Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17(8):2371–2380. https://doi.org/10.1200/JCO.1999.17.8.2371 CrossRefPubMed

15.

Kwan KW, Chlebowski RT (2009) Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin Breast Cancer 9(4):219–224. https://doi.org/10.3816/CBC.2009.n.037 CrossRefPubMed

16.

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical O (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967. https://doi.org/10.1200/JCO.2013.54.0914 CrossRefPubMed

17.

De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S (2015) Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol 96(1):34–45. https://doi.org/10.1016/j.critrevonc.2015.04.011 CrossRefPubMed

18.

Erven K, Weltens C, Nackaerts K, Fieuws S, Decramer M, Lievens Y (2012) Changes in pulmonary function up to 10 years after locoregional breast irradiation. Int J Radiat Oncol Biol Phys 82(2):701–707. https://doi.org/10.1016/j.ijrobp.2010.12.058 CrossRefPubMed

19.

Bower JE, Bak K, Berger A, , Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA, Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical O (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol 32(17):1840–1850. https://doi.org/10.1200/JCO.2013.53.4495 CrossRefPubMedPubMedCentral

20.

Eisner A, Luoh SW (2011) Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res 36(10):867–885. https://doi.org/10.3109/02713683.2011.594202 CrossRefPubMedPubMedCentral

21.

Majkowska-Mlynarczyk A, Kinalski M, Zaczek-Kucharska E (2007) The thyroid gland function assessment in women after mastectomy and chemotherapy during breast cancer therapy. Endokrynol Pol 58(5):397–402PubMed

22.

Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 302(18):1985–1992. https://doi.org/10.1001/jama.2009.1568 CrossRefPubMed

23.

Hurria A, Muss H (2015) Special issues in older women with breast cancer. Adv Exp Med Biol 862:23–37. https://doi.org/10.1007/978-3-319-16366-6_3 CrossRefPubMed

24.

Hurria A, Naylor M, Cohen HJ (2013) Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA 310(17):1795–1796. https://doi.org/10.1001/jama.2013.280416 CrossRefPubMed

25.

National Cancer Institute (2015) Surveillance, epidemiology, and end result program. http://seer.cancer.gov/. Accessed 1 July 2017

26.

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA (2016) American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 34(6):611–635. https://doi.org/10.1200/JCO.2015.64.3809 CrossRefPubMed

27.

American Society of Clinical Oncology (2016) 2016 Cancer Survivorship Symposium. https://meetinglibrary.asco.org/browse-meetings/2016 Cancer Survivorship Symposium. Accessed 31 August 2017

28.

American Society of Clinical Oncology (2015) 2015 ASCO Annual Meeting. https://meetinglibrary.asco.org/browse-meetings/2015 ASCO Annual Meeting. Accessed 31 August 2017

29.

Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory G (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89CrossRefPubMed

30.

Moyer VA, Force USPST (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160(4):271–281. https://doi.org/10.7326/m13-2747

31.

Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30(30):3675–3686. https://doi.org/10.1200/JCO.2012.43.0116 CrossRefPubMedPubMedCentral

32.

Pan K, Chlebowski RT, Simon MS, Ray RM, Livaudais-Toman J, Sullivan SD, Stefanick ML, Wallace RB, LeBoff M, Bluhm EC, Paskett ED (2016) Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls. Breast Cancer Res Treat 156(3):567–576. https://doi.org/10.1007/s10549-016-3773-4 CrossRefPubMedPubMedCentral

33.

Arnold BJ, Cumming CE, Lees AW, Handman MD, Cumming DC, Urion C (2001) Tamoxifen in breast cancer: symptom reporting. Breast J 7(2):97–100CrossRefPubMed

34.

Day R, Ganz PA, Costantino JP (2001) Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project’s Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 93(21):1615–1623CrossRefPubMed

35.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62. https://doi.org/10.1016/S0140-6736(04)17666-6 CrossRefPubMed

36.

Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, Investigators NCMS (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391. https://doi.org/10.1056/NEJMoa1103507 CrossRefPubMed

37.

Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Ales-Martinez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dube P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H (2014) Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 32(14):1427–1436. https://doi.org/10.1200/JCO.2013.51.2483 CrossRefPubMedPubMedCentral

38.

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, Investigators I-I (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041–1048. https://doi.org/10.1016/S0140-6736(13)62292-8 CrossRefPubMed

39.

Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL (2003) Implementation of the Women’s Health Initiative study design. Ann Epidemiol 13(9 Suppl):S5–17CrossRefPubMed

40.

Jordan JH, Thwin SS, Lash TL, Buist DS, Field TS, Haque R, Pawloski PA, Petersen HV, Prout MN, Quinn VP, Yood MU, Silliman RA, Geiger AM (2014) Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat 146(2):401–409. https://doi.org/10.1007/s10549-014-3021-8 CrossRefPubMedPubMedCentral

41.

Park BW, Hwang SY (2012) Unmet Needs and Their Relationship with Quality of Life among Women with Recurrent Breast Cancer. J Breast Cancer 15(4):454–461. https://doi.org/10.4048/jbc.2012.15.4.454 CrossRefPubMedPubMedCentral

42.

Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30(29):3578–3587. https://doi.org/10.1200/JCO.2011.39.5640 CrossRefPubMedPubMedCentral

43.

Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR (2017) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a Nationwide, multicenter. Prospective Longitudinal Study. J Clin Oncol 35(5):506–514. https://doi.org/10.1200/JCO.2016.68.5826 CrossRefPubMed

44.

Piccart MRE, vant Veer L, Slaets L, Delaloge S, Viale G, et al (2016) Primary analysis of the EORTC 10041/BIG 3-04 MINDACT study: A prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. In: American Association of Cancer Research, New Orleans, LA

45.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373(21):2005–2014. https://doi.org/10.1056/NEJMoa1510764 CrossRefPubMedPubMedCentral

Titel: Breast cancer survivorship: state of the science
verfasst von: Kathy Pan
Arti Hurria
Rowan T. Chlebowski
Publikationsdatum: 13.01.2018
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4650-5

Springer Medizin

Breast cancer survivorship: state of the science

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Functional transcriptomic annotation and protein–protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer

BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia

Long-term use of basal insulin and the risk of breast cancer

Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study

Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie